Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
Condition(s):Ovarian CancerLast Updated:April 1, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Ovarian CancerLast Updated:April 1, 2020Completed
Condition(s):High Grade Serous CarcinomaLast Updated:December 5, 2023Recruiting
Condition(s):Endometrial Serous Adenocarcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC1 Uterine Corpus Cancer; Stage IIIC2 Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus CancerLast Updated:August 29, 2023Terminated
Condition(s):Endometrial Serous Adenocarcinoma; Stage I Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus CancerLast Updated:May 29, 2015Not yet recruiting
Condition(s):Mucinous Cystic Tumor With Moderate Dysplasia; Mucinous Cystadenoma of Pancreas; Mucinous Cystadenocarcinoma of Pancreas; Benign Neoplasm of PancreasLast Updated:November 2, 2016Terminated
Condition(s):Uterine Serous CarcinomaLast Updated:March 20, 2024Recruiting
Condition(s):Uterine Serous CarcinomaLast Updated:August 14, 2023Completed
Condition(s):Endometrial Serous Adenocarcinoma; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid NeoplasmLast Updated:March 7, 2024Recruiting
Condition(s):Endometrial Serous AdenocarcinomaLast Updated:November 15, 2023Recruiting
Condition(s):Uterine CarcinomaLast Updated:March 17, 2023Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.